Today, Pfizer announced a “landmark agreement” with the Trump Administration. The press release promised lower drug costs and a revival of U.S. manufacturing. President Donald Trump touted that Pfizer would cut Medicaid drug prices for low-income Americans and sell new medicines at a “most-favored-nation” price — but only in exchange for tariff relief.
In reality, it appears to be a multi-billion dollar effort to entrench Pfizer’s failed gene-transfer platforms for decades to come.
The deal secures a $70 billion commitment to U.S. R&D — a down payment on Pfizer’s next wave of gene-based products:
- Cancer “vaccines”
- Obesity injections
- Expanded vaccine portfolio (flu, RSV, bird flu, more)
- Chronic disease biologics in inflammation & immunology
Pfizer itself spelled it out:
“With this agreement in place, Pfizer can fully focus on delivering the next generation of cures… in areas like oncology, obesity, vaccines, and inflammation and immunology.”
This comes after Pfizer’s COVID-19 gene-based products have already been linked to catastrophic injuries, deaths, and disabilities worldwide. Instead of scrutiny, the company is rewarded with protection and growth.
Hellbound and Down 